MX380780B - TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR. - Google Patents
TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR.Info
- Publication number
- MX380780B MX380780B MX2018012456A MX2018012456A MX380780B MX 380780 B MX380780 B MX 380780B MX 2018012456 A MX2018012456 A MX 2018012456A MX 2018012456 A MX2018012456 A MX 2018012456A MX 380780 B MX380780 B MX 380780B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- combination therapy
- methyl
- acceptable salt
- pi3k
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321307P | 2016-04-12 | 2016-04-12 | |
| PCT/US2017/026099 WO2017180385A1 (en) | 2016-04-12 | 2017-04-05 | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012456A MX2018012456A (es) | 2019-03-07 |
| MX380780B true MX380780B (es) | 2025-03-12 |
Family
ID=58548918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012456A MX380780B (es) | 2016-04-12 | 2017-04-05 | TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11564929B2 (enExample) |
| EP (1) | EP3442528B1 (enExample) |
| JP (2) | JP6911048B2 (enExample) |
| KR (1) | KR102418766B1 (enExample) |
| CN (1) | CN109310685B (enExample) |
| AU (1) | AU2017249988C1 (enExample) |
| CA (1) | CA3020918A1 (enExample) |
| ES (1) | ES2898952T3 (enExample) |
| MX (1) | MX380780B (enExample) |
| RU (1) | RU2754452C2 (enExample) |
| WO (1) | WO2017180385A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| WO2017180385A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |
| MX380779B (es) | 2016-04-12 | 2025-03-12 | Lilly Co Eli | Terapia combinatoria con inhibidores notch y cdk4/6 |
| JP7194022B2 (ja) | 2016-05-20 | 2022-12-21 | イーライ リリー アンド カンパニー | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| AU2018222749B2 (en) | 2017-02-17 | 2024-04-18 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
| EP3703750B1 (en) | 2017-11-01 | 2024-12-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides |
| MA50564A (fr) | 2017-11-06 | 2020-09-16 | Hutchinson Fred Cancer Res | Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0001232A3 (en) | 1996-12-23 | 2001-02-28 | Elan Pharmaceuticals Inc San F | Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds |
| AU768269B2 (en) | 1998-10-02 | 2003-12-04 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Apoptosis inducing agents and methods |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| WO2007004743A1 (en) | 2005-07-05 | 2007-01-11 | Fujifilm Corporation | Copolymer and polymerizable composition |
| JP4822751B2 (ja) | 2005-07-05 | 2011-11-24 | 富士フイルム株式会社 | 共重合体およびその製造方法 |
| WO2008112249A1 (en) | 2007-03-13 | 2008-09-18 | Trustees Of Columbia University In The City Of New York | Synergistic interaction of notch-1 inhibitors with glucocorticoids |
| CN101674834B (zh) | 2007-03-28 | 2013-06-12 | 环状药物公司 | 布鲁顿氏酪氨酸激酶(Bruton's tyrosine kinase)抑制剂 |
| EP2178844A1 (en) | 2007-08-14 | 2010-04-28 | Eli Lilly & Company | Azepine derivatives as gamma-secretase inhibitors |
| US20090181944A1 (en) | 2008-01-11 | 2009-07-16 | John Frederick Boylan | Method for cancer therapy |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| US20120213029A1 (en) * | 2009-08-26 | 2012-08-23 | Frxsh Ag | Apparatus and method for mixing of a material to be mixed |
| US8637493B2 (en) | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
| CN102085372A (zh) | 2009-12-04 | 2011-06-08 | 中国医学科学院基础医学研究所 | Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途 |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| JP5737903B2 (ja) | 2010-10-26 | 2015-06-17 | 三菱重工業株式会社 | 航空機用配管支持構造 |
| JO3003B1 (ar) * | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| JO3148B1 (ar) | 2011-07-27 | 2017-09-20 | Lilly Co Eli | مركب مثبط لإشارات مسار notch |
| AR087405A1 (es) | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| WO2014193898A1 (en) | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| EP3035964B1 (en) | 2013-08-20 | 2020-09-23 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| AU2015338974B2 (en) | 2014-10-31 | 2021-08-26 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| MX2018000999A (es) | 2015-07-24 | 2018-11-09 | Oncotracker Inc | Moduladores de gamma secretasa para el tratamiento de disfuncion del sistema inmunologico. |
| MX380779B (es) | 2016-04-12 | 2025-03-12 | Lilly Co Eli | Terapia combinatoria con inhibidores notch y cdk4/6 |
| WO2017180385A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |
| JP7194022B2 (ja) | 2016-05-20 | 2022-12-21 | イーライ リリー アンド カンパニー | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
| US20190209581A1 (en) | 2016-08-31 | 2019-07-11 | Eli Lilly And Company | Dosage regimen for treatment of solid tumors |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| MA50564A (fr) | 2017-11-06 | 2020-09-16 | Hutchinson Fred Cancer Res | Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase |
-
2017
- 2017-04-05 WO PCT/US2017/026099 patent/WO2017180385A1/en not_active Ceased
- 2017-04-05 KR KR1020187032282A patent/KR102418766B1/ko active Active
- 2017-04-05 ES ES17717989T patent/ES2898952T3/es active Active
- 2017-04-05 EP EP17717989.2A patent/EP3442528B1/en active Active
- 2017-04-05 RU RU2018138626A patent/RU2754452C2/ru active
- 2017-04-05 CA CA3020918A patent/CA3020918A1/en active Pending
- 2017-04-05 AU AU2017249988A patent/AU2017249988C1/en active Active
- 2017-04-05 JP JP2018553368A patent/JP6911048B2/ja active Active
- 2017-04-05 CN CN201780036176.4A patent/CN109310685B/zh active Active
- 2017-04-05 US US16/093,117 patent/US11564929B2/en active Active
- 2017-04-05 MX MX2018012456A patent/MX380780B/es unknown
-
2021
- 2021-07-07 JP JP2021112585A patent/JP7278331B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109310685B (zh) | 2021-10-29 |
| EP3442528B1 (en) | 2021-05-26 |
| AU2017249988B2 (en) | 2022-10-27 |
| JP2019511529A (ja) | 2019-04-25 |
| JP7278331B2 (ja) | 2023-05-19 |
| MX2018012456A (es) | 2019-03-07 |
| RU2754452C2 (ru) | 2021-09-02 |
| CN109310685A (zh) | 2019-02-05 |
| AU2017249988C1 (en) | 2023-02-16 |
| JP2021169474A (ja) | 2021-10-28 |
| JP6911048B2 (ja) | 2021-07-28 |
| KR102418766B1 (ko) | 2022-07-08 |
| AU2017249988A1 (en) | 2018-11-01 |
| WO2017180385A1 (en) | 2017-10-19 |
| RU2018138626A3 (enExample) | 2020-09-21 |
| RU2018138626A (ru) | 2020-05-13 |
| KR20180129917A (ko) | 2018-12-05 |
| US20210177859A1 (en) | 2021-06-17 |
| US11564929B2 (en) | 2023-01-31 |
| EP3442528A1 (en) | 2019-02-20 |
| ES2898952T3 (es) | 2022-03-09 |
| CA3020918A1 (en) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX380780B (es) | TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR. | |
| MX380779B (es) | Terapia combinatoria con inhibidores notch y cdk4/6 | |
| ZA201807585B (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| Strickland et al. | Targeting drivers of melanoma with synthetic small molecules and phytochemicals | |
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| MX381475B (es) | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. | |
| PH12019500892A1 (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) | |
| MX2021002886A (es) | Terapia de combinacion para el tratamiento de cancer de mama triple negativo. | |
| RU2017131430A (ru) | Способ лечения рака, ассоциированного с мутацией ras | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| PH12013502099A1 (en) | 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one for use in the treatment of adenoid cystic carcinoma | |
| TN2018000338A1 (en) | Methods of treating pediatric cancers | |
| BR112018002941A2 (pt) | métodos para tratar câncer pancreático metastático usando terapias de combinação compreendendo irinotecano lipossomal e oxaliplatina | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| MY164705A (en) | Imidazo [4,5-c] quinolin - 2 - one compound and its use as pi3 kinase / mtor dual inhibitor | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| MX2011012491A (es) | Administracion continua de cilengitida en tratamientos contra el cancer. | |
| WO2018102261A3 (en) | Boronic derivatives hydroxamates as anticancer agents | |
| WO2014115859A3 (ja) | 分子標的併用腫瘍治療・予防薬 | |
| MX394957B (es) | Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1". | |
| HK1255939A1 (zh) | 用於治疗癌症之组合疗法 | |
| MX2022002179A (es) | Combinacion de poziotinib con inhibidores del vegfr2 y sus metodos de utilizacion. | |
| NZ742470A (en) | Combination therapy for cancer | |
| HK40051941A (en) | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |